Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection

  • Son, Ho Sung (Department of Surgery, Kosin University College of Medicine) ;
  • Shin, Yeon Myung (Department of Surgery, Kosin University College of Medicine) ;
  • Park, Kwang Kuk (Department of Surgery, Kosin University College of Medicine) ;
  • Seo, Kyung Won (Department of Surgery, Kosin University College of Medicine) ;
  • Yoon, Ki Young (Department of Surgery, Kosin University College of Medicine) ;
  • Jang, Hee Kyung (Department of Pathology, Kosin University College of Medicine) ;
  • Lee, Sang-Ho (Department of Surgery, Kosin University College of Medicine) ;
  • Yang, Song I (Department of Surgery, Kosin University College of Medicine) ;
  • Kim, Jeong Hoon (Department of Surgery, Kosin University College of Medicine)
  • Received : 2014.07.17
  • Accepted : 2014.09.18
  • Published : 2014.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: At present, a human epidermal growth factor receptor 2 (HER2)-based concept of tumor biology has been established, and trastuzumab ($Herceptin^{(R)}$; Genentech/Roche, San Francisco, CA, USA), a monoclonal humanized antibody directed against HER2, is a pivotal agent for the management of HER2 positive (HER2+) metastatic breast cancer. It is also known that HER2 has a predictive value in gastric cancer; however, its association with the prognosis of this disease remains uncertain. The purpose of this study was to evaluate both the relationship between HER2 overexpression in the tumors of gastric cancer patients, and the prognosis of these patients who have had curative resection. Materials and Methods: A total of 139 consecutive patients with gastric cancer who underwent surgery at the Kosin University Gospel Hospital between October 2011 and March 2012 were included in this retrospective study. All tumor samples were examined for HER2 expression by immunohistochemistry. A retrospective review of the medical records was conducted to determine the correlation between the presence of HER2 overexpression and clinicopathological factors. Results: The HER2+ rate was 15.1%. HER2 overexpression was associated with histological grade (P=0.044) and Lauren classification (P=0.036). There was no significant difference in the 2-year overall survival between HER2+ and HER2- patients (P=0.396). Multivariate analysis showed that HER2 was not an independent prognostic factor. Conclusions: HER2 overexpression in tumors was associated with histological grade and Lauren classification in gastric cancer patients with curative resection. However, HER2 was not an independent prognostic factor for gastric cancer in our study.

Keywords

References

  1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  2. National Cancer Institute. SEER Cancer Statistics Review, 1975-2006 [Internet]. Bethesda (MD): National Cancer Institute; 2009 [cited 2010 Mar 5]. Available from: http://www. joplink.net/prev/201003/ref/16-001.html.
  3. Jørgensen JT, Hersom M. HER2 as a Prognostic marker in gastric cancer: a systematic analysis of data from the literature. J Cancer 2012;3:137-144. https://doi.org/10.7150/jca.4090
  4. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474. https://doi.org/10.1245/s10434-010-0985-4
  5. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-516. https://doi.org/10.1038/312513a0
  6. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-1052.
  7. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 2013;24:2360-2364. https://doi.org/10.1093/annonc/mdt232
  8. Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordr) 2011;34:89-95.
  9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331. https://doi.org/10.1016/S0092-8674(00)81871-1
  10. Oren M. Lonely no more: p53 finds its kin in a tumor suppressor haven. Cell 1997;90:829-832. https://doi.org/10.1016/S0092-8674(00)80347-5
  11. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393. https://doi.org/10.1016/j.humpath.2007.02.005
  12. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777. https://doi.org/10.1016/j.humpath.2008.11.014
  13. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24. https://doi.org/10.1097/PAI.0b013e31821c821c
  14. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-842. https://doi.org/10.1136/jcp.2010.076570
  15. Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 2011;20:94-100. https://doi.org/10.1097/PDM.0b013e3181fc02b7
  16. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011;58:383-394. https://doi.org/10.1111/j.1365-2559.2011.03760.x
  17. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30- year follow-up. J Clin Oncol 1992;10:1044-1048. https://doi.org/10.1200/JCO.1992.10.7.1044
  18. Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, et al. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer 1994;56:61-65.
  19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. https://doi.org/10.1126/science.3798106
  20. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J
  21. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-568. https://doi.org/10.1081/CNV-100103852
  22. Latif Z, Watters AD, Bartlett JM, Underwood MA, Aitchison M. Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int 2002;89:5-9. https://doi.org/10.1046/j.1464-410X.2002.02526.x
  23. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278. https://doi.org/10.1093/annonc/mdi064
  24. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009;101:1306-1307. https://doi.org/10.1093/jnci/djp341

Cited by

  1. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101) vol.19, pp.None, 2014, https://doi.org/10.1007/s10120-015-0518-8
  2. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer vol.9, pp.None, 2014, https://doi.org/10.2147/ott.s100979
  3. Clinicopathological factors associated with HER2-positive gastric cancer : A meta-analysis vol.96, pp.44, 2014, https://doi.org/10.1097/md.0000000000008437
  4. Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer vol.8, pp.14, 2014, https://doi.org/10.18632/oncotarget.14968
  5. Characterization of potential driver mutations involved in human breast cancer by computational approaches vol.8, pp.30, 2014, https://doi.org/10.18632/oncotarget.17225
  6. Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Sampl vol.17, pp.1, 2014, https://doi.org/10.5230/jgc.2017.17.e6
  7. Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy vol.13, pp.1, 2014, https://doi.org/10.14216/kjco.17003
  8. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer vol.17, pp.None, 2014, https://doi.org/10.1186/s12876-016-0561-x
  9. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature vol.15, pp.None, 2014, https://doi.org/10.1186/s12957-017-1132-5
  10. Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma vol.13, pp.1, 2014, https://doi.org/10.1080/19932820.2018.1466573
  11. SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer vol.2019, pp.None, 2014, https://doi.org/10.1155/2019/6754040
  12. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2 vol.26, pp.2, 2014, https://doi.org/10.3233/hab-170327
  13. Overexpression of HER2/Neu in gastric adenocarcinoma and its correlation with clinicopathological parameters vol.10, pp.4, 2014, https://doi.org/10.4103/ccij.ccij_130_20